Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.62 0.88 −4.29%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

What it owns vs. what it owes End of fiscal 2025, 31 December 2025

Liabilities are $65.9M more than assets: shareholders’ equity is negative. What is a balance sheet?

31 December 2025 · total $89.4M

Owns

$70.0KLong-term assets
$119.0KOther short-term assets
$89.2MCash & short-term investments

Funded by

$155.2MOther liabilities

Debt is 0.0% of the total; liabilities are $65.9M more than assets.

Dec '25
Total current assets
89.28
Total non-current assets
0.07
Total Assets
89.35
Total current liabilities
5.24
Total non-current liabilities
149.98
Total liabilities
155.22
Common Equity (Total)
(65.87)
Shareholders Equity (Total)
(65.87)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 12 Nov 2026